• darkblurbg

    Towards a cure for type 1 diabetes

    Antigen based therapies
    Medical Technology
    Stem Cells

  • Diabetes

    More than 400 million people worldwide suffer from diabetes. 10-20% have an autoimmune form of the disease where the immune system attacks and destroys the insulin-producing beta cells. Autoimmune diabetes is a chronic disease and there is currently no cure.

  • Product Development

    Diamyd Medical develops the diabetes vaccine Diamyd®, based on the exclusively licensed GAD molecule. The Company’s licensed technologies GABA and Gliadin also have the potential to become key pieces of the puzzle to prevent, treat or cure autoimmune diabetes.

  • Clinical Trials

    The development of Diamyd Medical’s licensed technologies for GAD, GABA and Gliadin, in combination or with other substances with various mechanisms of action, is carried out in clinical trials and preclinical studies. Six clinical trials are currently ongoing.

THE COMPANY

Diamyd Medical is a Swedish diabetes company active in the field of pharmaceutical development
The share is listed on Nasdaq Stockholm First North (ticker: DMYD B)


Read More
  Quarterly Report 2, April 2016

Dear Shareholders

The second quarter of this fiscal year and the period thereafter have been exciting and eventful. We presented preliminary reports from three different ongoing combination studies with the diabetes vaccine Diamyd®: 1) DIABGAD (Diamyd®/ibuprofen/vitamin D); 2) DIAGNODE (intralymphatic injection of Diamyd®/vitamin D); 3) EDCR (Diamyd®/etanercept/vitamin D), and all have shown a good safety profile thus far. We applied for and, after the end of the period, received approval from both the Swedish Medical Products Agency and the Ethics Review Board for a certain extension of the DIAGNODE trial, and we are engaged in discussions regarding an extension of the GABA/Diamyd® trial in Birmingham/Alabama. An agreement was...

We aim to cure type 1 diabetes by first inducing immunological tolerance to the insulin-producing beta cells and then restore the functional beta cell mass by stem cell therapy.
Anders Essen-Möller, President and CEO